7:08 am Pfizer beats by $0.01, beats on revs; guides FY15 EPS below consensus, revs below consensus ( PFE) : Reports Q4 (Dec) earnings of $0.54 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus Estimate of $0.53; revenues fell 3.2% year/year to $13.12 bln vs the $12.83 bln consensus.
- Co issues downside guidance for FY15, sees EPS of $2.00-2.10, excluding non-recurring items, vs. $2.18 Capital IQ Consensus Estimate; sees FY15 revs of $44.5-46.5 bln vs. $47.37 bln Capital IQ Consensus Estimate.
- "As we look forward to 2015, we expect continued momentum with our pipeline, notably the potential U.S. approval of Ibrance (palbociclib) for advanced breast cancer, as well as anticipated strong growth in emerging markets and from our recent product launches in developed markets, including Eliquis, Xeljanz, Prevnar 13 in adults and Nexium 24HR. We are now in a position to commence over 20 registrational studies during the coming four years with candidates that are based upon strong science and target indications that have significant unmet need."
|
